Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

Sarepta stock fell after it agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular ...

Sarepta Therapeutics is pausing shipments of its gene therapy for muscular dystrophy following several patient deaths that have attracted attention from regulators. The company said late Monday ...

Key Takeaways The S&P 500 and Nasdaq reached record highs Monday, while the Dow advanced as well, in the wake of several strong earnings reports.Verizon Communications shares rose after the telecom ...

Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...

U.S. stock futures rise as investors brace for a high-stakes week packed with Tesla and Alphabet earnings and growing anxiety over Trumps looming tariff deadline. The Dow, S&P 500, and Nasdaq futures ...

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% ...

The Dow Jones Industrial Average slipped on Friday (July 18) amid reports that US President Donald Trump is pushing for ...

Sarepta Therapeutics shares plunge over 37% as FDA weighs halting shipments of its key gene therapy, Elevidys, after patient ...

Sarepta Therapeutics to lay off 493 workers, including 80 in Ohio, amid FDA probe, stock plunge, and concerns over Duchenne ...

Sarepta Therapeutics (NASDAQ: SRPT) stock fell 42% Wednesday following news of a second fatal acute liver failure case linked to its Duchenne muscular dystrophy treatment Elevidys. The sharp ...